Steminent Biotherapeutics Inc. (TPEX:7729)

Market Cap	6.12B +140.3%
Revenue (ttm)	n/a
Net Income	-204.46M
EPS	-3.03
Shares Out	80.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	432,313
Open	75.40
Previous Close	76.80
Day's Range	75.40 - 77.90
52-Week Range	37.85 - 95.60
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 18, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7729

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error